Promising cream for rare skin condition falls short in early trial

NCT ID NCT03363763

Terminated Disease control Sponsor: Aucta Pharmaceuticals, Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a sirolimus cream (0.2% and 0.4%) applied daily for 12 weeks to treat facial angiofibromas in children aged 2-21 with tuberous sclerosis complex. The goal was to see if the cream could safely reduce the size and redness of these skin growths. The trial was terminated early, so results are limited and no clear conclusions can be drawn.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANGIOFIBROMA OF FACE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Erythema exanthem Facies fibroma tuberous sclerosis tuberous sclerosis 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANGIOFIBROMA OF FACE TUBEROUS SCLEROSIS

Contacts and locations

Locations

Boston Children's Hospital

Boston, Massachusetts, 02115, United States
Children's Clinical Research Organization, Children's Hospital Colorado

Aurora, Colorado, 80045, United States
Children's Healthcare of Atlanta

Atlanta, Georgia, 30329, United States
Children's Hospital of Fudan University

Shanghai, 201102, China
Children's Hospital of Los Angeles, Division of Neurology

Los Angeles, California, 90027, United States
Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104, United States
LeBonheur Children's Hospital

Memphis, Tennessee, 38103, United States
Translational Genomics Research

Phoenix, Arizona, 85004, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.